Two Experts. One Protein. And the Mission That Binds Them
A CDI resaerch team has embarked on a drug discovery journey that may lead to new treatment for pediatric nonalcoholic fatty liver disease (NFLD. This serious condition is a troubling consequence of the rise in childhood obesity that can lead to diminished liver function later in life. According to the Centers for Disease Control and Prevention, one in five school-aged children (ages 6-19) is obese.
Antibiotic Resistance Hot Spots Identified
CDI investigator Gautam Dantas, PhD, led a study that surveyed ecosystems of bacteria and their capacity to resist antibiotics in low resource communities and identified areas ripe for bacteria to shuffle and share their resistance genes....More
Gordon Recognized for Leading Research on Microbiome
Public research, development and manufacturing company Agilent Technologies has recognized CDI Board Member and prominent researcher Jeffrey I. Gordon, MD, with a Thought Leader Award. The award supports his research into the role of the gut microbiome in human health. Dr. Gordon's work has begun to uncover the complex relationship between the tens of trillions of microbes that live in the gastrointestinal tract, our health status and our disease risks.